Mark Samuels has an extensive track record of leading complex life science collaborations, national infrastructure projects, and international trade deals. Well-versed in setting up research and development partnerships involving multiple stakeholders, some of his achievements include co-founding the Medicines Discovery Catapult, securing a $21m R&D investment from Teva Pharmaceuticals into the UK, co-chairing the transformation programme that established NICE’s evaluation programme for medical technologies, and chairing the board that established the UK Stem Cell Transplant clinical trials partnership. He is currently the CEO of the British Generic Manufacturers Association (BGMA), representing the industry that supplies four out of five medicines to the NHS. With executive and board-level roles across his sector – spanning government, academia, and the private sector – he is a powerful influence, bringing expertise, innovation and vision to his roles. He is a member of the Government’s Life Sciences Council, advising on the strategic direction and priorities for the UK’s life sciences industry.
Top 100 Influential People Entry
The Top 100 is set to develop a centre of excellence. A place to recognise a handful of the UK’s most successful and influential people.
Enter